Ferumoxytol: A new era of iron deficiency anemia treatment for patients with chronic kidney disease

Journal of Nephrology

Volumn 24, Issue 6, 2011, Pages 717-722

  Kowalczyk, Mariusz ^a   Banach, Maciej ^a   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chronic kidney disease; Ferumoxytol; Iron deficiency anemia

Indexed keywords

FERROUS FUMARATE; FERUMOXYTOL; HEMOGLOBIN; PLACEBO;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE REACTION; IRON DEFICIENCY ANEMIA; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NAUSEA; PARTICLE SIZE; PRURITUS; REVIEW; SINGLE DRUG DOSE; SLOW DRUG RELEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; COMORBIDITY; FERRIC COMPOUNDS; FERUMOXYTOL; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES;

EID: 80355135443     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000025     Document Type: Review

References (30)

1. Rastogi A, Nissenson AR. New approaches to the management of anemia of chronic kidney disease: beyond Epogen and Infed. Kidney Int. 2006;70:14-16.
2. National Kidney Foundation. KDOQI clinical practice guidelines for anemia of chronic disease. Am J Kidney Dis. 2001; 37:182-238.
3. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5)(Suppl 3): S11-S145.
4. Silverberg DS, Blum M, Agbaria Z, et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int. 1999;69 (Suppl 69):79-85.
5. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50(5):1694-1699.
6. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25(3):433-439.
7. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008;19(8):1599-1605.
8. Provenzano R, Schiller S, Rao M, Coyone D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):389-393.
9. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69(6):739-756.
10. Prince MR, Zhang HL, Chabra SG, Jacobs P, Wang Y. A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J XRay Sci Technol. 2003;11:231-240.
11. Ersoy H, Jacobs P, Kent CK, Prince MR. Blood pool MR angiography of aortic stent-graft endoleak. AJR Am J Roentgenol. 2004;182(5):1181-1186.
12. Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol. 2005;25(4):400-410.
13. Balakrishnan VS, Rao M, Kausz AT, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest. 2009;39(6):489-496.
14. Lawrence R. Development and comparison of iron dextran products. PDA J Pharm Sci Technol. 1998;52(5):190-197.
15. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004;15(Suppl 2): S93-S98.
16. Menth M, Röckel A, Abdelhamid S, Fiegel P, Walb D. Lowmolecular- weight protein-permeable cuprammonium rayon haemofilter. Nephrol Dial Transplant. 1992;7(8):844-847.
17. Fishbane S, Wagner J. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis. 2001;37(5):879-883.
18. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002;40(1):90-103.
19. Espósito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest. 2002;32(Suppl 1):42-49.
20. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant. 2004;19(3):561-565.
21. Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant. 2000;15(11):1827-1834.
22. Mossey RT, Sondheimer J. Listeriosis in patients with longterm hemodialysis and transfusional iron overload. Am J Med. 1985;79(3):397-400.
23. Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Hörl WH, Sunder-Plassmann G. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol. 2003; 14(10):2639-2644.
24. Guo D, Jaber BL, Lee S, et al. Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol. 2002;58(2):134-142.
25. Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52(5):907-915.
26. Jacobs P, Lewis J, Frigo T. Bleomycin detectable iron and percent transferrin saturation in the serum of patients receiving either ferumoxytol, iron gluconate or iron sucrose. J Am Soc Nephrol. 2004;15:546A.
27. Lewis J, Jacobs P, Frigio T. Comparison of free iron in ferumoxytol with other iron therapeutics. J Am Soc Nephrol. 2003;14:771A.
28. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008;52(5):897-906.
29. Banach M, Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother. 2010;11(16): 2575-2578.
30. Malyszko J, Zbroch E, Malyszko J, Mysliwiec M, Iaina A. The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci. 2010;6: 539-544.